论文部分内容阅读
目的检测Livin蛋白在人正常膀胱组织及上尿路移行细胞癌组织中的表达情况,并分析其表达与肿瘤临床分期、病理分级及肿瘤复发之间的关系。方法采用免疫组织化学法检测12例正常上尿路上皮组织切片及58例上尿路移行细胞癌组织标本及中Livin基因的表达情况。结果 Livin蛋白在正常上尿路上皮组织中无表达,而在移行细胞癌组织中高表达,阳性表达率为60.3%。Livin蛋白在不同性别、年龄及是否伴有淋巴结转移患者中的表达差异无统计学意义(P>0.05),而不同分期及分级的组间表达差异具有统计学意义(P<0.05)。随访9-45个月(平均29.3个月),肿瘤患者中共有27例出现局部或膀胱复发,总复发率为46.6%,其中Livin表达阴性组3年估计无瘤复发生存率为49.5%,而Livin表达阳性患者3年估计无瘤复发生存率为30.1%,二者之间差异显著(P=0.04)。结论 Livin在正常上尿路移行上皮组织中不表达,在上尿路移行细胞癌组织中高表达,Livin的表达与上尿路移行细胞癌分期、分级密切相关,与肿瘤复发密切相关。
Objective To detect the expression of Livin protein in human normal bladder tissue and upper urinary tract transitional cell carcinoma (TCC), and to analyze its relationship with clinical stage, pathological grade and tumor recurrence. Methods Immunohistochemical method was used to detect the expression of Livin gene and 12 specimens of normal upper urinary tract epithelial tissue and 58 cases of upper urinary tract transitional cell carcinoma. Results Livin protein was not expressed in epithelial epithelial epithelial cells but highly expressed in transitional cell carcinoma. The positive rate of Livin protein was 60.3%. There was no significant difference in the expression of Livin protein among different sexes, ages and patients with lymph node metastasis (P> 0.05), but there was significant difference between different stages and grades (P <0.05). During the follow-up period of 9-45 months (average 29.3 months), there were 27 cases of tumor recurrence with local or bladder recurrence, the total recurrence rate was 46.6%. The 3-year survival rate of tumor-negative recurrence in Livin-negative group was 49.5% The 3-year estimated recurrence-free survival rate of patients with positive Livin expression was 30.1%, a significant difference between the two (P = 0.04). Conclusions Livin is not expressed in the normal epithelium of the upper urinary tract and is highly expressed in the upper urinary transitional cell carcinoma. The expression of Livin is closely related to the staging and grading of upper urinary tract transitional cell carcinoma, which is closely related to tumor recurrence.